PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-65.74%
Both yoy net incomes decline, with GNPX at -17.92%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-40.21%
Negative yoy D&A while GNPX is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
147.42%
Deferred tax of 147.42% while GNPX is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-33.50%
Both cut yoy SBC, with GNPX at -51.17%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
2171.95%
Well above GNPX's 193.21% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
577.15%
A yoy AP increase while GNPX is negative at -231.79%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-447.03%
Negative yoy usage while GNPX is 214.13%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-33.50%
Negative yoy while GNPX is 0.00%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-13.29%
Negative yoy CFO while GNPX is 7.14%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
19.79%
CapEx growth of 19.79% while GNPX is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
19.79%
We expand invests by 19.79% while GNPX is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
-207.32%
We cut debt repayment yoy while GNPX is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
104.75%
We slightly raise equity while GNPX is negative at -71.09%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.